An FDA advisory panel on Bristol Myers Squibb Opdivo and Merck Keytruda will examine if PD-L1 tumor expression should limit ...

Shares of Bristol Myers Squibb Co. BMY rallied 1.86% to $50.94 Tuesday, on what proved to be an all-around favorable trading ...

US poised to approve KarXT as new antipsychotic treatment for disorder, which could offer reduced side-effects ...

Delayed diagnosis and treatment of CCCA result in insufficiently aggressive therapy and risks an avoidable consequence, ...

Several studies revealed high cardiovascular risk in people with type 1 diabetes, including in those who are asymptomatic and ...

More than 75% of the cohort started a TNF inhibitor during the selected time frame. For the rest, JAK inhibitors were the ...

The revisions signal a shift toward looking at MS more as a biologically based disease, noted Xavier Montalban, MD, PhD, of ...

BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target ...

Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

Discover Bristol-Myers Squibb's groundbreaking patent for personalized SLE treatment, utilizing IKZF3 gene expression to optimize dosage for better patient outcomes.

The hits just keep on coming for Bristol Myers Squibb staffers amid the company's cost-savings program.  | Bristol Myers ...

There was a lot to cheer outside Enterprise Center Tuesday morning. Riders ready to brave their bikes with the St. Louis ...